Abstract 225P
Background
Elderly men (>/=75yo) comprise 25% of patients with prostate cancer. However, they are typically underrepresented in pivotal trials. Limited data suggest these patients receive less intensive treatment with greater toxicity, despite comparable response rates. Our retrospective study examined treatment patterns and outcomes in a real-world population with castration-resistant prostate cancer (CRPC).
Methods
Using the multi-centre electronic CRPC Australian Database (ePAD), we extracted clinicopathologic, treatment and outcome data. Descriptive statistics were used to report data in patients aged >/=75yo and <75yo. Comparisons between these groups were analysed using T-tests and Fisher’s exact tests. Time-to-event analyses were performed using the Kaplan-Meier method.
Results
We identified 753 men with CRPC, with 327 (43%) aged >/=75yo. Elderly patients had higher rates of ischemic heart disease (33% vs 16% in younger patients, p=0.004) and stroke (11% vs 5%, p=0.007). They were more likely to receive only one line of systemic therapy (67% vs 40%, p<0.001), and androgen receptor signalling inhibitors (ARSIs) were most commonly prescribed as initial therapy (78% vs 48%, p<0.001). Enrolment in clinical trials was less frequent (5% vs 15%, p<0.001). There was no statistical difference in treatment duration or PSA50 response rates with ARSIs or docetaxel (Table). Overall, serious adverse events (SAEs) leading to hospitalisation, dose delays or modifications occurred in more elderly men (24% vs 16%, p=0.003), with a trend towards greater SAEs in those receiving docetaxel or ARSIs. Elderly patients were more likely to stop docetaxel due to toxicity (39% vs 21%, p=0.02). Table: 225P
First-line therapy for CRPC
<75yrs | >/=75years | p-value | |
Abiraterone | N=58 | N=84 | |
PSA50 response rate | 24 (41%) | 43 (51%) | 0.30 |
Treatment duration | 11.9 months | 10.6 months | 0.52 |
Serious adverse event | 10 (17%) | 24 (29%) | 0.16 |
Cessation due to toxicity | 6 (10%) | 12 (14%) | 0.61 |
Enzalutamide | N=119 | N=159 | |
PSA50 response rate | 63 (53%) | 94 (59%) | 0.33 |
Treatment duration | 11.5 months | 11.5 months | 0.87 |
Serious adverse event | 20 (17%) | 36 (23%) | 0.29 |
Cessation due to toxicity | 8 (7%) | 16 (10%) | 0.39 |
Docetaxel | N=155 | N=41 | |
PSA50 response rate | 79 (51%) | 18 (44%) | 0.48 |
Treatment duration | 6.0 months | 4.6 months | 0.24 |
Serious adverse event | 28 (18%) | 10 (24%) | 0.38 |
Cessation due to toxicity | 32 (21%) | 16 (39%) | 0.02 |
Conclusions
In our real-world cohort, elderly men had greater comorbidities and received fewer lines of systemic therapy. Although there was no difference in treatment response or duration, elderly patients experienced higher SAE rates. Prospective studies are required to further evaluate long-term outcomes in these patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Astellas, AstraZeneca, Janssen, Amgen.
Disclosure
E. Kwan: Honoraria (self): Janssen; Honoraria (self), Travel/Accommodation/Expenses: Ipsen; Research grant/Funding (institution), Travel/Accommodation/Expenses: Astellas; Research grant/Funding (institution), Travel/Accommodation/Expenses: Pfizer; Research grant/Funding (institution): AstraZeneca; Research grant/Funding (institution): Bristol-Myers Squibb; Research grant/Funding (institution): Merck Serono. F.X. Parnis: Leadership role, Administrative Board: Janssen; Leadership role, Administrative Board: Astellas; Leadership role, Administrative Board: Bayer. All other authors have declared no conflicts of interest.
Resources from the same session
210P - Prognostic value of sarcopenia in metastatic renal cell carcinoma patients: A systematic review
Presenter: Angeline Tancherla
Session: e-Poster Display Session
211P - The impact of low muscle mass to overall survival in bladder cancer patients undergoing chemotherapy: A systematic review and meta-analysis
Presenter: Karunia Japar
Session: e-Poster Display Session
212P - Stage I non-seminoma testicular cancer: Adjuvant management and outcomes
Presenter: Gaik Tin Quah
Session: e-Poster Display Session
213P - Stage I seminoma testicular cancer: Predictors of relapse and outcomes for adjuvant carboplatin vs active surveillance
Presenter: Gaik Tin Quah
Session: e-Poster Display Session
214P - Study of treatment outcome in adults with TFE related RCC
Presenter: Ajaykumar Singh
Session: e-Poster Display Session
215P - Analysis of spatial heterogeneity of responses in metastatic sites with nivolumab in renal cell carcinoma
Presenter: Venkata Pradeep Babu Koyyala
Session: e-Poster Display Session
216P - Clinical profile and treatment outcome of testicular seminoma treated at tertiary care centre in Chennai
Presenter: Sivasubramaniam Kumaravelu
Session: e-Poster Display Session
220P - A cost-effectiveness analysis of systemic therapy for metastatic hormone-sensitive prostate cancer
Presenter: Winnie Sung
Session: e-Poster Display Session
221P - Patient-reported sexual and urinary function in nonmetastatic castration-resistant prostate cancer (nmCRPC) when treated with apalutamide (APA) vs placebo (PBO) and ongoing androgen deprivation therapy (ADT) in SPARTAN
Presenter: Hiroji Uemura
Session: e-Poster Display Session
222P - Tolerability and treatment response to darolutamide (DARO) in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) in the phase III ARAMIS trial
Presenter: Matthew R. Smith
Session: e-Poster Display Session